COVID-19 :: Rigel Pharmaceuticals, Inc. (RIGL)
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia | Immunotherapy
R406 besylate | Syk inhibitor - Active metabolite of Fostamatinib | InvivoGen
Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
APS Publications on Twitter: "Platelets and tyrosine kinase inhibitors: clinical features, mechanism of action and effects on physiology - new Review in @AJPCellPhys https://t.co/G9SSGG4Hrq #platelets #articlesinpress https://t.co/oJ0JnJMjho" / Twitter
Rigel's fostamatinib successfully meets endpoint in chronic ITP trial
Mechanism of Action | TAVALISSE HCP
Fostamatinib Disodium Hexahydrate: A Novel Treatment for Adult Immune Thrombocytopenia
Mechanism of Action | TAVALISSE HCP
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib - Nichola Cooper, Ivy Altomare, Mark R. Thomas, Phillip L. R. Nicolson, Steve P. Watson, Vadim Markovtsov, Leslie K. Todd,
Mechanism of action: R406 is a Syk kinase inhibitor. a, inhibition of... | Download Scientific Diagram
Thrombopoietin receptor agonists: ten years later | Haematologica
![PDF] Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d711e8e86aeae763b8fc11f910a59ea4140c53c6/6-Figure1-1.png "PDF] Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) | Semantic Scholar")
PDF] Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) | Semantic Scholar
Frontiers | Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Medicina | Free Full-Text | Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms
Frontiers | Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
IJMS | Free Full-Text | Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach
Fostamatinib - Wikipedia
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion - Alessandro Lucchesi, Bruno Fattizzo, Valerio De Stefano, Marco Ruggeri, Sergio Siragusa, Nicola Vianelli, Francesco
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
Frontiers | Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Mechanism of Action | TAVALISSE HCP
Favorable aspects and potential difficulties foreseen by the EP with... | Download Scientific Diagram
JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
Fostamatinib: A Review in Chronic Immune Thrombocytopenia | SpringerLink
Advances in targeted therapy for malignant lymphoma | Signal Transduction and Targeted Therapy
Novel therapies for immune thrombocytopenia - Kuter - 2022 - British Journal of Haematology - Wiley Online Library
Recent advances in the mechanisms and treatment of immune thrombocytopenia - eBioMedicine
